Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label givinostat study in boys aged 2 to <6 years with Duchenne muscular dystrophy
NL-OMON60111Phase 2Recruiting
- Sponsor
- Italfarmaco
- Start
- Nov 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of givinostat in Duchenne muscular dystrophy (DMD) (2 cohorts), sponsored by Italfarmaco. Primary endpoints: AUC0-T,ss, Cmax,ss and 3 more. Started Nov 2024; status: recruiting.
02
Drugs
givinostat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON60111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60111.